LY03020
Pharmaceutical compound
From Wikipedia, the free encyclopedia
LY03020 is a dual serotonin 5-HT2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease.[1][2][3] It is taken orally as a controlled-release formulation.[1] The drug is under development by Luye Pharma Group.[1][2][3] As of February 2026, it is in phase 1 clinical trials for both indications.[1][2][3] The chemical structure of LY03020 does not yet appear to have been disclosed.[1]
Other namesLY-03020; LPM787000048; LPM-787000048
ATC code
- None
| Clinical data | |
|---|---|
| Other names | LY-03020; LPM787000048; LPM-787000048 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT2C receptor agonist |
| ATC code |
|
